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Introduction: Montelukast has been proven to assure a protective effect against exercise-
induced bronchoconstriction.
Aim: To verify exactly when montelukast begins protection in asthmatic children by evaluating
different time intervals between dosing and challenge.
Methods: In a double blind, placebo-controlled, three day doses, crossover study, patients
were randomized to receive in sequence treatment with either a placebo or montelukast
and assigned to one of seven groups that were tested 1, 2, 3, 4, 5, 6 and 8 h after drug admin-
istration, respectively. For each group, the exercise challenge was always performed at the
same hour on the first and third days of treatment.
Results: Sixty-nine asthmatic children took part in the study. On day 3, the mean FEV1 % fall
from baseline was 25.54 (95% CI Z 21.63/29.46) and 14.89 (95% CI Z 11.85/17.92) for the
placebo and active drug (p < 0.05), respectively. On day 1, the mean fall of FEV1 was 28.20
(95% CIZ 24.46/31.94) and 19.01 (95% CIZ 15.71/22.31) for the placebo and montelukast
(p < 0.05), respectively. Clinical protection was achieved in 21 (30%) and 33 (48%) subjects
by montelukast on the first and third days, respectively.
Conclusions: Montelukast assured protection against exercise-induced bronchoconstriction
from the first through the eighth hour from thefirst day of treatment. However, individual
susceptibility to protection was evident since some individuals were not protected at any; EIB, Exercise-induced bronchoconstriction; FEV1, forced expiratory volume in 1 s; LTs, cysteinyl
tor antagonists; MNT, Montelukast.
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evaluated in the follow-up management.
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Prevention of exercise-induced bronchoconstriction (EIB)
has been indicated as a major goal for total control of
asthma, and GINA guidelines underline the importance of
achieving EIB prevention for optimal child development.1
Mechanisms of EIB are not completely clear but mediators
released by inflammatory cells that act as potent bron-
choconstrictor agents, such as histamine and cysteinyl
leukotrienes (LTs), appear to be involved.2 The role of LTs
has been clearly demonstrated indirectly by the protective
effect of leukotriene-receptor antagonists (LTRA) such as
montelukast (MNT) on EIB in both adults and children.3e9
Since airway inflammation is important in the patho-
genesis of airway responses to exercise, inhaled cortico-
steroids are frequently used to control EIB.10 However,
inhaled corticosteroids need to be used for 4 weeks or more
prior to exercising in order to have a significant protective
effect on EIB.11 Because some children are not protected by
treatment,12 additional drugs are required. The use of
short-acting beta-2 agonists is recommended, but their
usefulness as prophylactic agents for EIB is limited to under
2.5 h.13 Thus, in relation to the unpredictable time interval
between drug administration and exercising/playing in
children, other drugs with longer efficacy, such as long-
acting beta-2 agonists or LTRA, might be preferred. MNT
has been proven to assure a protective effect when used
either on a regular basis14 or as a single dose treat-
ment.15,16 However, knowing that oral MNT gives a peak
plasma concentration between 3 and 4 h in both adults and
children,17 the matter concerning the early time course of
its protection after a single or a few doses remains to be
clarified. It has also been demonstrated that the thera-
peutic effect of MNT is influenced by individual response
since some patients can be considered non-responders to
the drug.6
The aim of this study was to verify the MNT time of onset
of protection in relation to single patient responses to the
drug. We verified the effects against EIB in asthmatic chil-
dren by evaluating different time intervals between dosing
and exercise challenge (EC), after a single dose and after
three days of MNT therapy.
Methods
Patients
One hundred and ten children with asthma as defined by
the American Thoracic Society,18 having a resting FEV1 of
70% or more and a positive clinical history of EIB, were
screened by an EC. Sixty-nine children, who met the
criteria of a fall of 20% or more in FEV1 post-exercise,
participated in the study. All the patients were using
inhaled steroids (fluticasone dipropionate, average dose200 mg/d, or equivalent), which they continued to do
throughout the study period.
To be admitted to the study, the children had to have
been free from airway infections in the previous six weeks.
Asthma had been stable in all patients, without exacerba-
tions or necessary hospitalizations due to the disease in the
last 6 months.
Study design
Within a few days after a baseline EC, the children were
randomized to a double-blind, placebo-controlled, three
day doses, crossover study design. Each patient was
randomized by a computer-generated schedule to receive
in sequence double-blind treatments with either a placebo
or MNT (5 mg). Patients in sequence 1 received MNT, then
crossed over to a matching placebo; vice versa for patients
in sequence 2. Placebo and active treatments were sepa-
rated by a 7e10 day wash-out period. MNT or matched
placebo capsules were prepared and dispensed in a rando-
mised order with the randomisation code kept by pharmacy
staff at the Verona Hospital pharmacy. The pharmaceutical
company that manufactures MNT (Singulair, Merck, Sharp
and Dohme Ltd, Roma, Italy) declined to supply matching
placebo, so MNT and placebo tablets were encapsulated to
assure blindness.19
Each child was assigned to one of seven groups in order
to perform the EC at different time intervals after drug
administration, which was always at 8.00 A.M. On day one,
the challenge was performed by the different groups 1, 2,
3, 4, 5, 6 and 8 h after drug administration, respectively.
Treatment was continued as a single daily dose for three
consecutive days, then a third challenge was performed at
the same time of day. This last EC was done to identify
those children who would be considered non-responders to
MNT,20,21 thereby influencing our finding the time course
between dosing and onset of protection.
In order to eliminate any influence of changes in pollen
exposure in sensitive patients, the study was done during
the winter.
Exercise challenge test
Standardized EC test protocol was applied22e24 and tests
were done in an air-conditioned room (19e21 C; relative
humidity <50%). Following the EC, FEV1 was measured at 1,
3, 5, 10, 15, 20 and 30 min.
Short acting b2-agonists were not allowed for 12 h prior
to the challenge.
End points
The maximal percentage fall in FEV1 from baseline values
after the EC (DFEV1) was considered the endpoint. FEV1
values were plotted against time for each treatment.
1792 D.G. Peroni et al.Percentage of protection was calculated as [(Ps  Pt)/
Ps] $ 100 where Ps is the percentage fall in FEV1 at the
screening visit, and Pt is the fall after each treatment.
24
Clinical protection was considered achieved if the
percentage fall (DFEV1) after receiving MNTwas one-half or
less of the percentage fall after receiving the placebo.
The Hospital Ethical Committee of the coordinating
hospital approved the study and both children and care-
givers gave written informed consent.
Statistical analysis
The effects of treatment were compared using DFEV1
expressed as percentage of the pre-challenge baseline. A
bi-variate analysis was done; the Fisher-Pitman permuta-
tion test for paired replicates was used to test the
hypothesis that the effect of MNT on DFEV1 is different
from the effect of a placebo (when the sample size exceeds
13, the significance level was calculated by 200,000 Monte
Carlo simulations). Subsequently, the effect of treatment
was evaluated by estimating the parameters of the
following multi-variable random-effects model:
DFEVijktZb0 þ b1  Treatk þ b2)Dayj þ b3)Hourt
þ b4)Treatk)Hourt þ b5)DFEVBASi þ b6)Agei
þ ui þ εijkt
where b0, and b6 are the model coefficients, Treatk is
a binary variable for treatment (k Z 0 for placebo and
k Z 1 for MNT), Dayj is a binary variable for the day of
treatment (jZ 0 for first day and jZ 1 for third day), Hourt
is the number of hours elapsed between drug administra-
tion and EC of subject i (t Z 1, 2, ., 8), DFEVi
BAS is the
DFEV1 of subject i at baseline (i Z 1, 2, .., 69), ui is the
random-effect of subject i (that is, the random deviation of
the mean measurement of the i-th subject from the overall
mean b0). DFEVijkt is the DFEV1 of the i-th subject that
receives the k treatment on day j and hour t. The term εijkt
is the within-subject error component of the model. The
carry-over effect was tested on the whole sample and on
the day-1 and day-3 subgroups by adding a variable “carry-
over” in the above mixed-effect model.
All statistical calculations were done using Stata 10
(StataCorp LP, College Station, Texas, USA).Table 1 Descriptive statistics of the sample characteristics in t
Time
(h)
No. Age
(years)
Baseline
%DFEV1
%DFEV1
1-day after
placebo
%DFEV1
1-day aft
monteluk
1 12 10.0 (2.4) 34.5 (14.2) 27.6 (13.6) 18.1 (11.
2 8 10.9 (1.8) 41.8 (15.2) 35.4 (15.4) 30.2 (18.
3 9 10.4 (1.6) 31.5 (11.4) 24.1 (15.5) 17.4 (11.
4 9 11.5 (1.3) 26.9 (6.0) 22.9 (14.9) 21.2 (26.
5 9 11.2 (2.1) 32.4 (9.8) 33.4 (18.7) 25.3 (13.
6 9 10.6 (2.4) 31.0 (9.8) 26.1 (15.1) 10.5 (3.6
8 13 10.8 (1.6) 30.6 (9.5) 30.0 (13.2) 17.8 (14.Results
The children’s age and their baseline DFEV1 are summa-
rized in Table 1.
Safety
No adverse event was observed during the study period. All
the children enrolled completed the study.
Efficacy
At the EC enrollment screening, the mean DFEV1 for the
children participating in the study was 32.5 (95% CI Z 29.8
to 35.3). At baseline, DFEV1 ranged from 41.8 (95%
CI Z 29.0 to 54.5) in the second hour group to 26.9 (95%
CI Z 22.3 to 31.5) in the fourth hour group (Table 1).
On day 3, the mean DFEV1 of the cohort was 25.0 (95%
CI Z 21.3 to 28.6) and 14.7 (95% CIZ 11.8 to 17.6) for the
placebo and MNT (p < 0.001), respectively. On day 1, the
mean DFEV1 for the whole population was 28.5 (95%
CI Z 24.9 to 32.1) and 18.6 (95% CIZ 15.5 to 21.8) for the
placebo and MNT (p < 0.001), respectively. Table 1 shows
the mean DFEV1 differences between the placebo and MNT
for the different time groups on the first and third days of
treatment.
Fig. 1a and b shows the levels of DFEV1 for each patient
at the single hour of EC from baseline to the first and third
days after taking MNT or the placebo, respectively. Data
regarding the percentage of protection for the placebo and
MNT in the 7 time groups and after the first and third day
doses are reported in Table 2.
Twenty-one subjects (CP Z 30%, 95% CI Z 20% to 43%)
obtained clinical protection by the LTRA after a single daily
dose. After three days of treatment, this number grew to 33
subjects, with nearly 50% (CPZ 48%, 95% CIZ 36% to 60%)
of clinically protected children in the study population.
These results show that a noticeable fraction of patients
does not appear to be clinically protected by the active drug
on the first or on the third day of treatment. After three
days of drug administration, 36 patients (52%) were not
clinically protected according to our definition of clinical
protection and can be defined as “non-responders” to MNT.
The DFEV1 values for the first and the third days of
placebo or MNT treatment regarding the 33 responder
subjects are given in Table 3. Fig. 2 shows the time effect ofhe 7 timing groups (mean  standard deviation).
er
ast
DFEV1
1 day
difference
%DFEV1
3-day after
placebo
%DFEV1
3-day after
montelukast
DFEV1
3-day
difference
5) 9.5 (12.1) 24.7 (13.8) 14.4 (12.3) 10.3 (17.1)
0) 5.2 (10.7) 30.9 (19.2) 28.2 (16.1) 2.6 (6.9)
1) 6.8 (15.4) 18.3 (11.8) 11.4 (8.3) 6.9 (7.0)
8) 10.7 (12.7) 16.1 (12.4) 10.6 (8.1) 5.5 (9.1)
9) 8.2 (11.9) 32.8 (16.9) 16.8 (14.5) 18.8 (19.1)
) 15.8 (13.8) 22.5 (11.8) 12.0 (9.3) 10.6 (8.3)
3) 12.2 (12.1) 29.2 (15.8) 12.3 (9.6) 16.9 (14.1)
Fig. 1 (a and b) Levels of DFEV1 for each patient at the first hour after administration on the first and third days after taking (a)
montelukast and (b) a placebo.
Time-effect of montelukast 1793the therapy in the 33 responders. The relationship between
time and the differences on the first day between DFEV1
after placebo and DFEV1 after MNT was modeled using
a linear regression. No statistically significant trend for
a time effect was observed. Fig. 2 also shows that the
responders showed a significant improvement in DFEV1values from the first hour, induced by the MNT treatment
(11.4%, 95% CI Z 3.2% to 19.6%) that remained relatively
constant in the various time groups.
An estimation of the coefficients of a random-effect
model showed that the effect of treatment was statistically
significant (b1Z 5.4, 95% CIZ 9.71.1, pZ 0.013) and
Table 2 Percentage of protection (PoP) for placebo and Montelukast in the 7 timing groups (mean percentage and 95%
confidence interval).
Time (h) 1st-day PoP
Placebo
1st-day PoP
Montelukast
3rd-day Pop
Placebo
3rd-day PoP
Montelukast
1 15.2 (10.9e41.4) 42.2 (13.3e71.1) 27.1 (8.2e46.1) 53.1 (22.2e84.1)
2 14.4 (2.8e31.6) 36.6 (17.9e55.4) 27.6 (14.2e41.0) 45.3 (25.0e65.5)
3 16.9 (3.2e30.7) 37.1 (21.8e52.4) 30.2 (18.1e42.2) 50.0 (35.2e64.7)
4 16.7 (3.2e30.1) 41.3 (29.3e53.4) 33.4 (23.0e43.9) 52.9 (42.8e63.1)
5 11.1 (2.7e25.0) 35.6 (22.6e48.5) 24.1 (9.8e38.3) 53.0 (42.8e63.1)
6 11.5 (1.3e24.3) 39.5 (28.2e50.9) 23.5 (10.4e36.6) 54.4 (45.5e63.3)
8 9.2 (1.8e20.3) 40.3 (30.4e50.3) 19.8 (8.1e31.4) 55.5 (47.6e63.4)
1794 D.G. Peroni et al.that there was a statistically significant difference in DFEV1
mean levels on the first and third days (b2 Z 3.5, 95%
CI Z 5.6 to 1.4, p Z 0.001). In addition, we found
a statistically significant interaction between treatment
and number of elapsed hours (p-value of the LR-
test Z 0.014). This means that there was a statistically
significant difference between the time effect of the
placebo group (b3 Z 0.8, 95% CI Z 0.3 to 1.8) and of the
group treated with MNT (b3Z 0.4, 95% CIZ 1.4 to 0.7).
The estimated coefficient of determination R2 of the model
was 0.34. This shows that the large variability of responses
observed in patients can only be partially captured by the
proposed model.
The carry-over effect was tested in the whole sample
and in the day-1 and day-3 subgroups by adding a variable
“carry-over” to the mixed-effect model. This effect was
not statistically significant in all cases.Discussion
Our results confirm the inter-patient variability of response
to MNT in patients with EIB. It has been previously reported
that 35e78%4,25e28 of patients (both children and adults) can
be non-responders to the drug. However, the heterogeneity
of therapeutic responses in asthma has been observed also
for glucocorticoids and b2 agonists.
25 For example, it has
been shown that single doses of inhaled salmeterol or for-
moterol cause prolonged bronchodilatation (>12 h) and
extended bronchoprotection against EIB in children; some
children achieve full protection for more than 12 h whereas
others are only partially protected or not at all.29Table 3 DFEV1 values at the first and third day of placeb
(mean  standard deviation).
Time
(h)
No. of
subjects
(Tot. Z 33)
ΔFEV1
1st-day after
placebo
ΔFEV1
1st-day after
montelukast
ΔF
1s
dif
1 7 26.1 (16.8) 15.0 (12.3) 11
2 0 e e e
3 3 31.0 (16.3) 13.6 (11.5) 17
4 4 27.1 (17.6) 12.5 (7.6) 14
5 5 40.6 (12.5) 32.9 (9.8) 7
6 4 19.2 (14.6) 9.7 (3.2) 6
8 10 31.3 (13.2) 15.3 (13.6) 16In our study, some patients were not protected by MNT at
any hour and day following drug administration. This was
especially evident in patients assessed 2 h after dosing,
where half of them did not respond to the drug. This
strongly influenced the results observed 2 h after dosing. If,
by chance, this had occurred in the group randomized to the
challenge 1 h after dosing, and if we had not also performed
the challenge after three days of treatment, we would have
reached the wrong conclusion that no protection was ach-
ieved 1 h after dosing. This, however, was the case, but only
in several patients that we considered ”responders”. These
findings may obviously have relevant clinical implications
for individual patient management of asthma.
A limit to our study is that we did not evaluate any single
parameter that could be used to identify the non-
responders. It has been estimated that 60e80% of inter-
patient variability response to LT modifiers may be attrib-
utable to genetic variations.20,30 Genetic variability in
5-lipoxygenase biosynthetic and receptor pathway gene
loci may influence LT production and subsequent response
to LTRA.31 CYSLTR2 and ALOX5 polymorphisms may predis-
pose a minority of individuals to excessive LT concentra-
tions, yielding a distinct asthma phenotype most likely to
respond to LTRA pharmacotherapy.31
The strength of our study is that we investigated
different time frames after single doses and that the
challenges were repeated after three days of treatment,
when the steady state of MNT pharmacokinetics is reason-
ably achieved and thus non-responder subjects could be
easily identified.17
At present, few studies have dealt with LTRA onset of
action. In a previous pediatric study we found, in a smallero or Montelukast treatment in the 33 responder subjects
EV1
t-day
ference
ΔFEV1
3rd-day after
placebo
ΔFEV1
3rd-day after
montelukast
ΔFEV1
3rd-day
difference
.1 (15.3) 28.4 (16.9) 7.4 (7.6) 21.0 (11.9)
e e e
.3 (23.8) 20.1 (5.6) 6.9 (2.9) 13.2 (5.0)
.6 (14.0) 20.3 (17.0) 7.8 (8.0) 12.5 (9.3)
.6 (13.3) 40.9 (14.6) 14.5 (14.0) 32.4 (18.4)
.0 (13.8) 24.4 (12.9) 7.1 (5.8) 17.3 (7.8)
.0 (8.8) 32.7 (16.2) 10.1 (9.5) 22.6 (8.7)
Fig. 2 Relationship between time and the differences on the first day between DFEV1 after placebo therapy and DFEV1 after MNT
therapy in the 33 responders.
Time-effect of montelukast 1795number of patients, a significant protective effect 12 h after
single administration of MNT, but not after 2 h.15 The lack of
an early protective effect can be explained by the less severe
DFEV1 in that study population, since only a few subjects had
a baseline DFEV1  20%, consequently with less room for
improvement after active treatment and more room for the
placebo effect.32 The protective effect of single MNT doses
was previously reported in adult asthmatics challenged after
1 h with cycle-ergometry while breathing frigid air33 or
tested on a treadmill 2 h after dosing.16,34 To the best of our
knowledge, data on the early effective onset of action by
montelukast obtained in children are novel. Our results are in
agreement with previous findings in adults because after
a single dose we obtained a significant reduction of DFEV1 in
the whole study population from the first hour after dosing.
Furthermore, considering the cumulative effect of time of
the drug, DFEV1 continued to be significantly reduced in the
hours followingMNT treatment. The relevant number of non-
responding subjects (52%) after three days of treatment is
a demonstration that a non-response is a complex event.
Although the MNT dose we used in our population is that
suggested by the manufacturers for children from 6 to 14
years of age,35 we can speculate that some children could
have disturbed bioavailability and therefore pharmacoki-
netics. It has been shown that MNT absorption is transporter
mediated and some genetic polymorphisms of transport
proteins are associated with reduced plasma concentrations
and poor response.36 Of course, a drug serum dosage would
have clarified this point, but this was not planned a priori;
and furthermore the effect of higher doses is worth investi-
gating. We can hypothesize that interferences with phar-
macokinetics can be due to the children’s weight variation
within groups, or physiological functions in response to thedrug such as vagal activity37 or association with atopy.38
Interference can also be attributable to the exercise load,
which can affect EIB severity.39 It is also worth considering
that in order to reduce the variability of EIB after the chal-
lenge in our study, we selected children with a high level of
EIB with a fall in FEV1 of at least 20%. Even if this could
explain the relatively high response rate (approximately
50%), we must keep in mind that, as with any study of
selected asthma patients, these data cannot be automati-
cally extrapolated to the general population of children with
asthma. In other words, our results shouldn’t be interpreted
in a clinical setting as an invitation to test the drug effects in
asthma patients with EIB by performing a challenge after
a few days of treatment, but as a reminder to evaluate and
check signs and symptoms of EIB after a period of mon-
telukast treatment, since some patients could be responders
from the very first doses whereas others may not respond to
the therapy at all.
In conclusion, we have shown that MNT was an effective
protection against EIB from the first hour after taking the
drug and that this protection lasted for up to 12 h. The
protective effect was evident on the first and third days of
treatment. We have also shown that there was an individual
susceptibility to MNT protection, being that some individ-
uals were not protected at any time after dosing. There-
fore, we conclude that in the clinical use of MNT to treat
EIB, individual responses to the drug should always be
carefully evaluated.Funding
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